I don't think that's the likely outcome, as the FDA cares little for European standards.
What it does mean is that the CE mark will be harder to get, so marketing new products into Europe will be harder. Thus the CE mark will be a more valuable asset, and provide a bigger moat against competitors.
Ann: CE Mark Update, page-286
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(4.17%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.2¢ | 1.2¢ | $3.318K | 277.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4850000 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 4285138 | 10 |
View Market Depth
| Last trade - 11.01am 04/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |